Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: Applying a "divide and conquer" strategy

被引:44
作者
Amin, EA [1 ]
Welsh, WJ [1 ]
机构
[1] Univ Missouri, Dept Chem & Biochem, St Louis, MO 63121 USA
关键词
D O I
10.1021/jm010236t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models have been obtained using comparative molecular field analysis (CoMFA) for a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs). The crystal structure of stromelysin-1 (MMP-3) was used to identify regions of the enzyme and inhibitors where steric and electrostatic effects correlate strongly with biological activity. A training set composed of a subset of inhibitors (#10-35), which differed only with regards to the substituent (n-alkyl, amide, carbamide and sulfonamide) on the piperazine distal nitrogen, yielded the most predictive CoMFA model, with r(2) values of 0.592 (cross-validated) and 0.989 (conventional); this model was further validated using test compounds from two inhibitor subsets. Investigation of various ligand conformations, inhibitor subsets, alignment schemes and partial charge formalisms was required to obtain satisfactory models. The greatest success was achieved by incorporating inertial alignment together with manual adjustment of the enzyme-docked inhibitors to ensure complementarity between the inhibitors' substituent conformations and the structural characteristics of the MMP-3 S1-S2' binding pockets. Key insights into the structure-activity relationship (SAR) obtained from this analysis for this inhibitor set are in agreement with experimentally observed data on stromelysin-1 biological activity and binding-site topology. In particular, the present study sheds new light on the steric and electrostatic requirements for ligand binding to the partly solvent-exposed S1-S2' area.
引用
收藏
页码:3849 / 3855
页数:7
相关论文
共 20 条
[1]   Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors [J].
Almstead, NG ;
Bradley, RS ;
Pikul, S ;
De, B ;
Natchus, MG ;
Taiwo, YO ;
Gu, F ;
Williams, LE ;
Hynd, BA ;
Janusz, MJ ;
Dunaway, CM ;
Mieling, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) :4547-4562
[2]  
[Anonymous], 1984, CHEMOMETRICS MATH ST
[3]   STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME [J].
BECKER, JW ;
MARCY, AI ;
ROKOSZ, LL ;
AXEL, MG ;
BURBAUM, JJ ;
FITZGERALD, PMD ;
CAMERON, PM ;
ESSER, CK ;
HAGMANN, WK ;
HERMES, JD ;
SPRINGER, JP .
PROTEIN SCIENCE, 1995, 4 (10) :1966-1976
[4]   Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding [J].
Botos, I ;
Scapozza, L ;
Zhang, DC ;
Liotta, LA ;
Meyer, EF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :2749-2754
[5]   INHIBITION OF MATRIX METALLOPROTEINASES BY N-CARBOXYALKYL PEPTIDES [J].
CHAPMAN, KT ;
KOPKA, IE ;
DURETTE, PL ;
ESSER, CK ;
LANZA, TJ ;
IZQUIERDOMARTIN, M ;
NIEDZWIECKI, L ;
CHANG, B ;
HARRISON, RK ;
KUO, DW ;
LIN, TY ;
STEIN, RL ;
HAGMANN, WK .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (26) :4293-4301
[6]   Design and synthesis of piperazine-based matrix metalloproteinase inhibitors [J].
Cheng, MY ;
De, B ;
Pikul, S ;
Almstead, NG ;
Natchus, MG ;
Anastasio, MV ;
McPhail, SJ ;
Snider, CE ;
Taiwo, YO ;
Chen, LY ;
Dunaway, CM ;
Gu, F ;
Dowty, ME ;
Mieling, GE ;
Janusz, MJ ;
Wang-Weigand, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :369-380
[7]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[8]  
DHANARAJ V, 1994, ATMOS ENVIRON, V28, P547
[9]   Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor [J].
Fernandez-Catalan, C ;
Bode, W ;
Huber, R ;
Turk, D ;
Calvete, JJ ;
Lichte, A ;
Tschesche, H ;
Maskos, K .
EMBO JOURNAL, 1998, 17 (17) :5238-5248
[10]   Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity [J].
Finzel, BC ;
Baldwin, ET ;
Bryant, GL ;
Hess, GF ;
Wilks, JW ;
Trepod, CM ;
Mott, JE ;
Marshall, VP ;
Petzold, GL ;
Poorman, RA ;
O'Sullivan, TJ ;
Schostarez, HJ ;
Mitchell, MA .
PROTEIN SCIENCE, 1998, 7 (10) :2118-2126